1-anilino-8-naphthalenesulfonate has been researched along with Granulocytic Leukemia, Chronic in 2 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ponatinib (AP24534) is a potent oral tyrosine kinase inhibitor that blocks native and mutated BCR-ABL, including the gatekeeper mutant T315I, which is uniformly resistant to tyrosine kinase inhibitors." | 2.77 | Ponatinib in refractory Philadelphia chromosome-positive leukemias. ( Bixby, D; Clackson, T; Cortes, JE; Deininger, MW; Druker, BJ; Flinn, I; Haluska, FG; Hu, S; Kantarjian, H; Mauro, MJ; Narasimhan, NI; O'Hare, T; Rivera, VM; Shah, NP; Talpaz, M; Turner, CD, 2012) |
| "We report on 8 chronic myeloid leukemia patients who developed serum lipase/amylase elevation during treatment with nilotinib." | 1.35 | Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. ( Amabile, M; Baccarani, M; Castagnetti, F; Gugliotta, G; Luatti, S; Martinelli, G; Palandri, F; Poerio, A; Rosti, G; Soverini, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palandri, F | 1 |
| Castagnetti, F | 1 |
| Soverini, S | 1 |
| Poerio, A | 1 |
| Gugliotta, G | 1 |
| Luatti, S | 1 |
| Amabile, M | 1 |
| Martinelli, G | 1 |
| Rosti, G | 1 |
| Baccarani, M | 1 |
| Cortes, JE | 1 |
| Kantarjian, H | 1 |
| Shah, NP | 1 |
| Bixby, D | 1 |
| Mauro, MJ | 1 |
| Flinn, I | 1 |
| O'Hare, T | 1 |
| Hu, S | 1 |
| Narasimhan, NI | 1 |
| Rivera, VM | 1 |
| Clackson, T | 1 |
| Turner, CD | 1 |
| Haluska, FG | 1 |
| Druker, BJ | 1 |
| Deininger, MW | 1 |
| Talpaz, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients With Refractory or Advanced Chronic Myelogenous Leukemia and Other Hematologic Malignancies[NCT00660920] | Phase 1 | 81 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Following Failure or Intolerance of Prior Therapy With Imatinib[NCT03171389] | Phase 2 | 81 participants (Anticipated) | Interventional | 2017-03-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for 1-anilino-8-naphthalenesulfonate and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antineoplastic Agents; Dose-Response Relationship, Drug; D | 2012 |
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antineoplastic Agents; Dose-Response Relationship, Drug; D | 2012 |
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antineoplastic Agents; Dose-Response Relationship, Drug; D | 2012 |
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antineoplastic Agents; Dose-Response Relationship, Drug; D | 2012 |
1 other study available for 1-anilino-8-naphthalenesulfonate and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure.
Topics: Adolescent; Adult; Aged; Amylases; Benzamides; Child; Drug Resistance, Neoplasm; Female; Humans; Ima | 2009 |